Helix receives patent for drug delivery technology
Helix Biopharma Corp HBP
Shares issued 13,776,415 Jan 6 close $0.33
Thu 7 Jan 99 News Release
An anonymous director reports
A significant composition patent has been issued to the company by the U.S.
Patent Office protecting the core technology used in its Biphasix
injectionless drug delivery technology. This new patent adds to the
existing portfolio of intellectual property, which includes patents for
drug delivery systems, anti-infective therapeutics and molecular sensor
technology.
The company's Biphasix system, which is capable of delivering a wide
variety of pharmaceuticals of varying sizes, weights and solubilities into
and through the skin, uses a proprietary, lipid-based, microencapsulation
process. Preliminary studies have shown that the Biphasix system may
enhance the availability of drugs in the body, leading to improved clinical
outcomes.
This injectionless drug delivery technology is particularly well suited to
biologically derived pharmaceuticals including proteins and DNA, which are
typically given by injection.
Helix has successfully conducted studies with a number of model compounds
such as insulin, interferon-a (widely used in the treatment of a common
sexually transmitted disease caused by the human papilloma virus) and
prostaglandin E(1) (used in the treatment of erectile dysfunction). These
initial applications have estimated potential markets in excess of
$4-billion (U.S.) annually. |
